Allosteric EGFR inhibitors and methods of use thereof
US12391671B2 · kind B2 · utility
0Cited by
4References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 10, 2022 |
| Grant date | Aug 19, 2025 |
| Priority date | — |
| Expiry date | Jan 28, 2044 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure relates to compounds that act as allosteric inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.